Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Precision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.
Cell Metab. 2023 Aug 8;35(8):1283-1303. doi: 10.1016/j.cmet.2023.07.006.
Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment targets to impede tumor progression in preclinical studies, with some advancing to clinical trials. However, the intricacy and adaptability of metabolic networks hinder the effectiveness of metabolic therapies. This review summarizes the metabolic targets for cancer treatment and provides an overview of the current status of clinical trials targeting cancer metabolism. Additionally, we decipher crucial factors that limit the efficacy of metabolism-based therapies and propose future directions. With advances in integrating multi-omics, single-cell, and spatial technologies, as well as the ability to track metabolic adaptation more precisely and dynamically, clinicians can personalize metabolic therapies for improved cancer treatment.
肿瘤中的代谢重编程不仅是一个生物学标志，还揭示了治疗的弱点。许多代谢分子已被证明具有作为治疗靶点的潜力，可在临床前研究中阻碍肿瘤进展，其中一些已进入临床试验。然而，代谢网络的复杂性和适应性阻碍了代谢疗法的有效性。本文综述了癌症治疗的代谢靶点，并概述了目前针对癌症代谢的临床试验现状。此外，我们还解析了限制基于代谢疗法疗效的关键因素，并提出了未来的方向。随着整合多组学、单细胞和空间技术的进展，以及更精确和动态地跟踪代谢适应的能力的提高，临床医生可以为患者量身定制代谢疗法，以改善癌症治疗效果。
